Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database
Patients were not recruited for nor enrolled in this study. This study is a retrospective
observational study. Data from medical records or insurance claims databases are anonymised
and used to develop a patient cohort. All diagnoses and treatment are recorded in the
course of routine medical practice. Actual number of patients could be less than , as it
is possible for a patient to be represented in more than one of the four arms (See
"Participant Flow: Overall Study" Table) because of the risk set sampling.
Observational Model: Case Control, Time Perspective: Retrospective
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).
The case index date (ID) was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case
GSK Clinical Trials
United States: No Health Authority